Filing Flows › Gilead Sciences (GILD) › Recalls, complaints & regulation
Gilead Sciences (GILD): recalls, clinical trials and Federal Register
Gilead Sciences (GILD) beyond its filings: 0 recalls in the last 12 months (2 in five years, 2 Class I); 2 Federal Register documents in a year; 91 active clinical trials.
Latest recalls
- 2024-10-09 · FDA drug · Veklury (remdesivir) for injection, 100 mg/vial, Single-Dose Vial, Rx only, Manufactured for: Gilead Sciences, Inc., Foster City, CA 94404, NDC 61958-2901-2
- 2022-01-05 · FDA drug · Veklury (remdesivir) for injection, 100 mg/vial, Single-Dose Vial, Rx only, Manufactured for: Gilead Sciences, Inc., Foster City, CA 94404, NDC 61958-2901-2
Gilead Sciences' latest quarter
Gilead Sciences, Q3 2026: revenue $8.3B (+7% year over year), operating margin 41.7%, net earnings $2.4B, operating cash flow $5.0B. The chart follows the revenue to costs, profit and cash.
Questions
Has Gilead Sciences had any recalls?
2 recalls on file over five years from the FDA, CPSC and NHTSA; 0 in the last 12 months.
How many clinical trials does Gilead Sciences have?
91 active studies on ClinicalTrials.gov, 33 in phase 3.
Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.